This issue of PET Clinics focuses on Evolving Role of PET in Assessing the Efficacy of Immunotherapy and Radiation Therapy in Malignant Disorders, and is edited by Drs. Charles B. Simone II, Nicolas Aide, and Abass Alavi (the Consulting Editor of PET Clinics). Articles will include: The Value of PET Imaging to Guide Target Delineation for Radiation Oncology; PET Imaging to Determine Radiation Dose, Adapt Radiation Plans, and Predict Patterns of Failure and Overall Survival for Non-small Cell Lung Cancer; The Utility of PET/CT for Radiation Oncology Planning, Surveillance, and Prognosis Prediction for Gastrointestinal Tumors; Evolving Role of PET Based Novel Quantitative Techniques to Detect Radiation-induced Complications; Current and Future PET Based Quantitative techniques to Assess Response to Radiation Therapy; Diagnosis, Staging, Radiation Treatment Response Assessment, and Prognostication; FDG PET/CT for Assessing Tumour Response to Immunotherapy and Detecting Immune-related Side Effects: A Checklist for the PET Reader; PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers; FDG PET/CT for Assessing Tumour Response to Immunotherapy in Lymphomas; FDG PET/CT for Assessing Tumour Response to Immunotherapy in Solid Tumours: Melanoma and Beyond; and more!
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. x 7. CME Accreditation Page - p. xi 8. Preface - p. xiii 9. 18F-Fludeoxyglucose PET/Computed Tomography for Assessing Tumor Response to Immunotherapy and Detecting Immune-Related Side Effects: A Checklist for the PET Reader - p. 1 10. 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Assessing Tumor Response to Immunotherapy in Solid Tumors: Melanoma and Beyond - p. 11 11. Current Evidence on PET Response Assessment to Immunotherapy in Lymphomas - p. 23 12. Programmed Cell Death-1/Ligand-1 PET Imaging: A Novel Tool to Optimize Immunotherapy? - p. 35 13. The Role of Positron Emission Tomography Imaging in Radiotherapy Target Delineation - p. 45 14. 18F-Fluorodeoxyglucose PET in Locally Advanced Non–small Cell Lung Cancer: From Predicting Outcomes to Guiding Therapy - p. 55 15. Diagnosis, Staging, Radiation Treatment Response Assessment, and Outcome Prognostication of Head and Neck Cancers Using PET Imaging: A Systematic Review - p. 65 16. The Utility of PET/Computed Tomography for Radiation Oncology Planning, Surveillance, and Prognosis Prediction of Gastrointestinal Tumors - p. 77 17. Evolving Role of Novel Quantitative PET Techniques to Detect Radiation-Induced Complications - p. 89 18. PET/Computed Tomography in Treatment Response Assessment in Cancer: An Overview with Emphasis on the Evolving Role in Response Evaluation to Immunotherapy and Radiation Therapy - p. 101
No hay muestra disponible
No hay ficha técnica disponible
This issue of PET Clinics focuses on Evolving Role of PET in Assessing the Efficacy of Immunotherapy and Radiation Therapy in Malignant Disorders, and is edited by Drs. Charles B. Simone II, Nicolas Aide, and Abass Alavi (the Consulting Editor of PET Clinics). Articles will include: The Value of PET Imaging to Guide Target Delineation for Radiation Oncology; PET Imaging to Determine Radiation Dose, Adapt Radiation Plans, and Predict Patterns of Failure and Overall Survival for Non-small Cell Lung Cancer; The Utility of PET/CT for Radiation Oncology Planning, Surveillance, and Prognosis Prediction for Gastrointestinal Tumors; Evolving Role of PET Based Novel Quantitative Techniques to Detect Radiation-induced Complications; Current and Future PET Based Quantitative techniques to Assess Response to Radiation Therapy; Diagnosis, Staging, Radiation Treatment Response Assessment, and Prognostication; FDG PET/CT for Assessing Tumour Response to Immunotherapy and Detecting Immune-related Side Effects: A Checklist for the PET Reader; PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers; FDG PET/CT for Assessing Tumour Response to Immunotherapy in Lymphomas; FDG PET/CT for Assessing Tumour Response to Immunotherapy in Solid Tumours: Melanoma and Beyond; and more!
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. x 7. CME Accreditation Page - p. xi 8. Preface - p. xiii 9. 18F-Fludeoxyglucose PET/Computed Tomography for Assessing Tumor Response to Immunotherapy and Detecting Immune-Related Side Effects: A Checklist for the PET Reader - p. 1 10. 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Assessing Tumor Response to Immunotherapy in Solid Tumors: Melanoma and Beyond - p. 11 11. Current Evidence on PET Response Assessment to Immunotherapy in Lymphomas - p. 23 12. Programmed Cell Death-1/Ligand-1 PET Imaging: A Novel Tool to Optimize Immunotherapy? - p. 35 13. The Role of Positron Emission Tomography Imaging in Radiotherapy Target Delineation - p. 45 14. 18F-Fluorodeoxyglucose PET in Locally Advanced Non–small Cell Lung Cancer: From Predicting Outcomes to Guiding Therapy - p. 55 15. Diagnosis, Staging, Radiation Treatment Response Assessment, and Outcome Prognostication of Head and Neck Cancers Using PET Imaging: A Systematic Review - p. 65 16. The Utility of PET/Computed Tomography for Radiation Oncology Planning, Surveillance, and Prognosis Prediction of Gastrointestinal Tumors - p. 77 17. Evolving Role of Novel Quantitative PET Techniques to Detect Radiation-Induced Complications - p. 89 18. PET/Computed Tomography in Treatment Response Assessment in Cancer: An Overview with Emphasis on the Evolving Role in Response Evaluation to Immunotherapy and Radiation Therapy - p. 101
No hay muestra disponible
No hay ficha técnica disponible
